1. Scrip
  2. >>Therapy Areas

Sanofi's SERD Candidate Founders In Advanced Breast Cancer

But Hope Remains For Earlier Setting

 
• By Ayisha Sharma

The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.

tissue of breast cancer
More Than Two-Thirds Of Advanced Breast Cancer Patients Have ER+/HER2- Tumors • Source: Alamy

Sanofi’s closely-watched SERD amcenestrant could succeed in earlier lines of metastatic breast cancer despite disappointment in an advanced disease study which has knocked the candidate from its pole position.

Amcenestrant missed the primary endpoint of progression free survival (PFS) in the Phase II AMEERA-3 study of locally advanced or...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.